Clinical trials: Cardiovascular Disease Risk Factors
Obesity, Overweight
Cardiovascular Outcomes Study of Naltrexone SR/Bupropion SR in Overweight and Obese Subjects With Cardiovascular Risk Factors (The Light Study)
The purpose of this study is to determine the effects of NB relative to placebo on major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in overweight and…
- Trial name
- NCT01601704
- Testing
- NB32, PBO, Weight Management Program
- Where
- 224 sites in United States
- Volunteers
- 8,910 people
- Sponsor
- Orexigen Therapeutics, Inc
Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor
Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
This retrospective observational target-trial emulation uses electronic health record data from the TriNetX US Collaborative Network to compare early treatment intensification strategies in adults with obesity, type 2 diabetes…
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Cardiovascular Disease Risk Factor, Kidney Disease, Type 2 Diabetes
- Trial name
- GLP1-SGLT2-CKM (NCT07465926)
- Testing
- GLP-1 receptor agonist, SGLT2 inhibitor
- Volunteers
- 451,036 people
- Sponsor
- Chung Shan Medical University
Atrial Fibrillation
Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
Primary Objective: Demonstrate the efficacy of Dronedarone in preventing major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or unplanned cardiovascular hospitalization…
- Trial name
- PALLAS (NCT01151137)
- Testing
- Dronedarone
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 3,236 people
- Sponsor
- Sanofi
Cardiovascular Diseases, Depression
Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors
This study will determine the effects of omega-3 fatty acid (FA) augmentation of sertraline on depression and cardiac endpoints after myocardial infarction (MI).
- Conditions
- Cardiovascular Diseases, Depression, Heart Diseases, Myocardial Infarction
- Trial name
- NCT00116857
- Testing
- Sertraline/omega-3, Sertraline/Corn Oil
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- Washington University School of Medicine
Rheumatoid Arthritis
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
This randomized, open-label, parallel-group, multicenter study will evaluate the rate of cardiovascular events with tocilizumab in comparison to etanercept in participants with rheumatoid arthritis (RA).
- Trial name
- NCT01331837
- Testing
- Etanercept, Tocilizumab
- Where
- 428 sites in United States, Argentina and 29 more
- Volunteers
- 3,080 people
- Sponsor
- Hoffmann-La Roche
Obstructive Sleep Apnea
Sleep Apnea Intervention for Cardiovascular Disease Reduction
Moderate to severe sleep apnea (a high number of breathing pauses on a sleep study) is a common health problem that is often associated with loud snoring and sleepiness.The medical term for this problem is obstructive sleep apnea…
- Trial name
- BestAIR (NCT01261390)
- Testing
- Conservative Medical Therapy (CMT), Active PAP with RT Support (Active-Beh), Active PAP with Behavioral Modification (Active+Beh)
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- Brigham and Women's Hospital
Cardiovascular Risk Factors
Study of Raisins Versus Alternative Snacks on Cardiovascular Risk Factors In Generally Healthy Subjects
This trial compared the effects of raisin intake on cardiovascular risk factors compared to common, commercially available, alternative snacks.
- Trial name
- NCT01260272
- Testing
- Alternative Snack Comparator, Raisins
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Louisville Metabolic and Atherosclerosis Research Center
Gout
Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
There is a mounting and clear association between hyperuricaemia, gout and the presence of traditional cardiovascular (CV) risk factors and CV event-equivalent conditions such as chronic kidney disease, metabolic syndrome, and…
- Trial name
- FORWARD (NCT02500641)
- Testing
- Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine
- Where
- 26 sites in Germany, Italy and 4 more
- Volunteers
- 196 people
- Sponsor
- Menarini International Operations Luxembourg SA
Sedentary Behavior, Cardiovascular Risk Factor
Combined Effects of Prolonged Sitting and Mental Stress on the Cardiovascular System
Prolonged sitting may pose a public health risk through its effects on the cardiovascular system, and may lead to impaired whole-body cardiovascular health, which includes both vascular and cerebrovascular function.
- Conditions
- Sedentary Behavior, Cardiovascular Risk Factor, Mental Stress, Cognitive Change
- Trial name
- NCT04207333
- Testing
- Mental Arithmetic Test
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Cardiovascular Risk Factor, Cardiovascular Diseases
Effects of Breaking up Prolonged Sitting on Postprandial Cardiometabolic Disease Risk Markers in South Asian Adults
The purpose of this study is to examine whether breaking up prolonged sitting with short regular bouts of walking can reduce blood sugar and cholesterol levels after eating, which are risk markers for Type 2 diabetes and heart…
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Physical Activity
- Trial name
- NCT03898206
- Testing
- Breaking up sitting with walking breaks (INT-SIT), Prolonged sitting (SIT)
- Where
- United Kingdom
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire
Blood Pressure, Hypertension
PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor
Program to Avoid Cerebrovascular Events through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor (PACESETTER) aims to assess the incorporation of its stroke intervention into 2 safety net/academic health…
- Conditions
- Blood Pressure, Hypertension, Mhealth
- Trial name
- NCT03401489
- Testing
- PACESETTER
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Northern California Institute of Research and Education
Hypercholesterolemia, Coronary Arteriosclerosis
Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)
This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.
- Trial name
- NCT00319449
- Testing
- Ezetimibe, Atorvastatin 10 mg
- Volunteers
- 22 people
- Sponsor
- Organon and Co
Cardiovascular Risk Factor, Stress
Stress-reduction Wellness Program for Midlife Black Women (B-SWELL)
This research study examines the unique cultural and gender-based factors that influence how midlife Black women experience stress and incorporate healthy lifestyle behaviors into daily life.
- Conditions
- Cardiovascular Risk Factor, Stress, Self Efficacy, Depressive Symptoms
- Trial name
- B-SWELL (NCT04404478)
- Testing
- B-SWELL: Midlife Black Women's Stress Reduction Wellness Program, WE: Wellness program for Midlife Black Women
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati